These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

362 related items for PubMed ID: 21346614

  • 1. Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.
    Muscatello MR, Bruno A, Pandolfo G, Micò U, Scimeca G, Romeo VM, Santoro V, Settineri S, Spina E, Zoccali RA.
    J Clin Psychopharmacol; 2011 Apr; 31(2):174-9. PubMed ID: 21346614
    [Abstract] [Full Text] [Related]

  • 2. Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.
    Bruno A, Micò U, Pandolfo G, Mallamace D, Abenavoli E, Di Nardo F, D'Arrigo C, Spina E, Zoccali RA, Muscatello MR.
    J Psychopharmacol; 2012 Nov; 26(11):1456-62. PubMed ID: 22351381
    [Abstract] [Full Text] [Related]

  • 3. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 12-week open-label preliminary study.
    Pessina E, Albert U, Bogetto F, Maina G.
    Int Clin Psychopharmacol; 2009 Sep; 24(5):265-9. PubMed ID: 19629012
    [Abstract] [Full Text] [Related]

  • 4. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 10-week open-label study.
    Ak M, Bulut SD, Bozkurt A, Ozsahin A.
    Adv Ther; 2011 Apr; 28(4):341-8. PubMed ID: 21437763
    [Abstract] [Full Text] [Related]

  • 5. A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy.
    Albert U, Marazziti D, Di Salvo G, Solia F, Rosso G, Maina G.
    Curr Med Chem; 2018 Apr; 25(41):5647-5661. PubMed ID: 29278206
    [Abstract] [Full Text] [Related]

  • 6. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials.
    Dold M, Aigner M, Lanzenberger R, Kasper S.
    Int J Neuropsychopharmacol; 2013 Apr; 16(3):557-74. PubMed ID: 22932229
    [Abstract] [Full Text] [Related]

  • 7. The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised study.
    Selvi Y, Atli A, Aydin A, Besiroglu L, Ozdemir P, Ozdemir O.
    Hum Psychopharmacol; 2011 Jan; 26(1):51-7. PubMed ID: 21308781
    [Abstract] [Full Text] [Related]

  • 8. Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials.
    Dold M, Aigner M, Lanzenberger R, Kasper S.
    Int J Neuropsychopharmacol; 2015 May 04; 18(9):. PubMed ID: 25939614
    [Abstract] [Full Text] [Related]

  • 9. A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder.
    Diniz JB, Shavitt RG, Fossaluza V, Koran L, Pereira CA, Miguel EC.
    J Clin Psychopharmacol; 2011 Dec 04; 31(6):763-8. PubMed ID: 22020357
    [Abstract] [Full Text] [Related]

  • 10. Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder.
    Storch EA, Goddard AW, Grant JE, De Nadai AS, Goodman WK, Mutch PJ, Medlock C, Odlaug B, McDougle CJ, Murphy TK.
    J Clin Psychiatry; 2013 Jun 04; 74(6):e527-32. PubMed ID: 23842022
    [Abstract] [Full Text] [Related]

  • 11. Effects of aripiprazole augmentation in treatment-resistant obsessive-compulsive disorder (a double blind clinical trial).
    Sayyah M, Sayyah M, Boostani H, Ghaffari SM, Hoseini A.
    Depress Anxiety; 2012 Oct 04; 29(10):850-4. PubMed ID: 22933237
    [Abstract] [Full Text] [Related]

  • 12. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder.
    Berlin HA, Koran LM, Jenike MA, Shapira NA, Chaplin W, Pallanti S, Hollander E.
    J Clin Psychiatry; 2011 May 04; 72(5):716-21. PubMed ID: 20816027
    [Abstract] [Full Text] [Related]

  • 13. Aripiprazole augmentation of incomplete treatment response in an adolescent male with obsessive-compulsive disorder.
    Storch EA, Lehmkuhl H, Geffken GR, Touchton A, Murphy TK.
    Depress Anxiety; 2008 May 04; 25(2):172-4. PubMed ID: 17340610
    [Abstract] [Full Text] [Related]

  • 14. Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison.
    Koran LM, McElroy SL, Davidson JR, Rasmussen SA, Hollander E, Jenike MA.
    J Clin Psychopharmacol; 1996 Apr 04; 16(2):121-9. PubMed ID: 8690827
    [Abstract] [Full Text] [Related]

  • 15. Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis.
    Veale D, Miles S, Smallcombe N, Ghezai H, Goldacre B, Hodsoll J.
    BMC Psychiatry; 2014 Nov 29; 14():317. PubMed ID: 25432131
    [Abstract] [Full Text] [Related]

  • 16. Effect of Ziprasidone Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: A 12-Week, Open-Label Uncontrolled Preliminary Study.
    Bruno A, Pandolfo G, Cedro C, Gallo G, De Felice M, Zoccali RA, Muscatello MR.
    Clin Neuropharmacol; 2016 Nov 29; 39(1):6-9. PubMed ID: 26757309
    [Abstract] [Full Text] [Related]

  • 17. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.
    Simpson HB, Foa EB, Liebowitz MR, Huppert JD, Cahill S, Maher MJ, McLean CP, Bender J, Marcus SM, Williams MT, Weaver J, Vermes D, Van Meter PE, Rodriguez CI, Powers M, Pinto A, Imms P, Hahn CG, Campeas R.
    JAMA Psychiatry; 2013 Nov 29; 70(11):1190-9. PubMed ID: 24026523
    [Abstract] [Full Text] [Related]

  • 18. Aripiprazole augmentation in treatment-refractory obsessive-compulsive disorder.
    Sarkar R, Klein J, Krüger S.
    Psychopharmacology (Berl); 2008 May 29; 197(4):687-8. PubMed ID: 18264798
    [No Abstract] [Full Text] [Related]

  • 19. Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: a randomized, open-label trial.
    Diniz JB, Shavitt RG, Pereira CA, Hounie AG, Pimentel I, Koran LM, Dainesi SM, Miguel EC.
    J Psychopharmacol; 2010 Mar 29; 24(3):297-307. PubMed ID: 19164490
    [Abstract] [Full Text] [Related]

  • 20. Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorder.
    Landeros-Weisenberger A, Bloch MH, Kelmendi B, Wegner R, Nudel J, Dombrowski P, Pittenger C, Krystal JH, Goodman WK, Leckman JF, Coric V.
    J Affect Disord; 2010 Feb 29; 121(1-2):175-9. PubMed ID: 19577308
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.